Literature DB >> 29128971

Perampanel-associated self-harm ideation after dosage increase.

Farid Kheloufi1,2, Anne Default1,2, Bruno Perrouty3, Olivier Blin1,2, Joëlle Micallef4,5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29128971     DOI： 10.1007/s00228-017-2348-6

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  3 in total

1.  Clinical experience with perampanel: focus on psychiatric adverse effects.

Authors:  Helen Coyle; Peter Clough; Paul Cooper; Rajiv Mohanraj
Journal:  Epilepsy Behav       Date:  2014-10-30       Impact factor: 2.937

2.  Increased risk of suicidality on perampanel (Fycompa®)?

Authors:  Bernd Huber
Journal:  Epilepsy Behav       Date:  2013-12-18       Impact factor: 2.937

3.  Concentration-effect relationships with perampanel in patients with pharmacoresistant partial-onset seizures.

Authors:  Barry E Gidal; Jim Ferry; Oneeb Majid; Ziad Hussein
Journal:  Epilepsia       Date:  2013-06-17       Impact factor: 5.864
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.